Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is 137.04 as of 2026-10-06T16:48:53.339Z.
Consensus retrieved: 2026-10-06T15:46:07.597Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:48:53.339Z.
Quote observation: 2026-10-06T16:45:30.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 287d76a0573bd8860cb44b5da68447fd0ebb3a8b825d5d877d7b45d0c886f980
Forward PE Ratio (137.04) = Dated Quote Price ($70.48) / Consensus Forward EPS ($0.51)
FORWARD PE RATIO
137.04
SECTOR MEDIAN · HEALTHCARE
19.59
median of 180 covered companies
CURRENT VS SECTOR MEDIAN
+599.54%
vs the sector median at left
RadNet, Inc.
Market Cap
$5.54B
Forward PE Ratio
137.04
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| RadNet, Inc. (RDNT) | $5.54B | 137.04 |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.51B | 29.15 |
| CG Oncology Inc. (CGON)vs › | $5.68B | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.73B | 54.02 |
| Doximity, Inc. (DOCS)vs › | $5.33B | 21.14 |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.30B | 49.99 |
| Sotera Health Company (SHC)vs › | $5.28B | 18.79 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.88B | N/A |
| CRISPR Therapeutics AG (CRSP)vs › | $5.19B | N/A |
| Cogent Biosciences, Inc. (COGT)vs › | $5.18B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
137.0
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $70.48, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.51 | $0.40 – $0.60 | 5 | 137.0x |
| 2027-12-31 | $0.89 | $0.75 – $1.12 | 4 | 79.5x |
| 2028-12-31 | $1.11 | $0.91 – $1.42 | 3 | 63.5x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
